Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

ALISO VIEJO, Calif., July 1, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) website indicates that an Abbreviated New Drug Application (ANDA) for a generic version of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules was submitted on March 7, 2011. The company received Paragraph IV certification notices on June 30, 2011.

Avanir intends to vigorously enforce its intellectual property rights relating to NUEDEXTA, which is protected by several patents covering the method of use of the product and its formulation. All of the currently issued patents are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Under the FDA's rules and regulations, if Avanir initiates a patent infringement suit to defend the patents identified in any Paragraph IV notice it receives within 45 days after its receipt of such notice, the FDA is prevented from approving the ANDA until the earlier of: (1) 30 months; (2) the expiration of the patents at issue; or (3) a decision in the infringement case that all of such patents are not infringed or invalid.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

About NUEDEXTA


'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- Michael DeMarco (42) erinnert sich kaum ... 2014 zugetragen hat. Seine Tochter Aly Demarco (13) wird ... - http://youtu.be/5cVoMCe0uiE „Man hat ... zu machen", erzählt Michael DeMarco . „Meine Frau ... Anhänger der CrossFit-Trainingsmethode. Ich war auf dem Fahrrad, stand ...
(Date:11/21/2014)... CORAL GABLES, Fla. , Nov. 20, 2014 /PRNewswire/ ... working to become the first U.S. commercial producer of ... signed a contract with INVAP to design ... Alachua, Fla. Mo-99 is the parent isotope ... nuclear medicine procedures worldwide. In 2012, Congress passed legislation ...
(Date:11/21/2014)... 2014   Wellcentive , the industry leader ... organizations, announced today being named one of the ... Award .  Sponsored by Intel, the world leader ... year, recognizes companies developing leading-edge technology and unique ... Wellcentive,s Mason Beard , ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... activity reported against CTCL, PTCL and Ovarian ... -- CuraGen,Corporation , a clinical-stage biopharmaceutical company ... the clinical development,program for belinostat, a histone ... clinical activity of belinostat,against cutaneous T-cell lymphoma ...
... 12, 2007 - Critical,Therapeutics, Inc. (Nasdaq: CRTX) today ... III clinical trial of ZYFLO CR(TM),(zileuton) extended-release tablets ... Asthma. ZYFLO CR was approved by the U.S. ... Critical Therapeutics,together with its co-promotion partner Dey, L.P. ...
Cached Medicine Technology:CuraGen Presents Update on Clinical Development Program for,Belinostat 2CuraGen Presents Update on Clinical Development Program for,Belinostat 3CuraGen Presents Update on Clinical Development Program for,Belinostat 4CuraGen Presents Update on Clinical Development Program for,Belinostat 5CuraGen Presents Update on Clinical Development Program for,Belinostat 6CuraGen Presents Update on Clinical Development Program for,Belinostat 7CuraGen Presents Update on Clinical Development Program for,Belinostat 8Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
(Date:11/23/2014)... November 23, 2014 Asher Milgrom, ... Aesthetics & Wellness was recently featured on ... is president and CEO of American Medical Aesthetics & ... Milgrom received a full scholarship to attend an M.D./Ph.D ... School at the University of Chicago, where his field ...
(Date:11/23/2014)... BambooFlooringChina.com , the world’s leader in bamboo flooring, ... flooring collection. Now, the business is announcing big discounts ... promotion is valid until Dec. 20, 2014. , The new ... dust-free surface, which makes it very easy to maintain. As ... wants to make its website the best shopping platform for ...
(Date:11/22/2014)... PrettyTailor , an outstanding dress ... big promotion. Customers can buy new dresses at its ... visit its website. , As a matter of fact, ... It mainly provides four types of wedding outfits, including ... girl dresses. It also provides a variety of occasion ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 Today, Dylan ... its new collection of wedding dresses; the business offers ... other related accessories for ladies worldwide, allowing them to ... manager of the company, this new collection of chic ... launch. Moreover, they are offered at discounted rates now. ...
(Date:11/22/2014)... 22, 2014 Nocturia is defined ... complaint that the individual has to wake at ... report “Nocturia – Pipeline Review, H2 2014” provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
Breaking Medicine News(10 mins):Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
... University of Illinois at Chicago College of Nursing has ... to improve the early growth and development of premature ... as poverty or minority status. , "Approximately half a ... United States," said Rosemary White-Traut, head of maternal-child nursing ...
... protein would let it thrive in upper airway, scientists say ... they,ve spotted a crucial step the deadly H5N1 bird flu ... , Since H5N1 first appeared in 1997, there have been ... Most of the human infections were the result of close ...
... EXCHANGE AND ... ELECTRONIC SUBMISSIONS, FOSTER ... its PC-LDM(TM) Suite that allows Pharmaceutical and,Biotechnology companies to instantly ... CDISC (Clinical Data Interchange,Standards Consortium) standard. FDA is anticipating that ...
... 50-70 million,sufferers, sleep disorders are one of the most ... Center on Sleep Disorder,Research. It should come as no ... disorders grows, so too does the market for,prescription sleep ... CNNMoney.com, the market for insomnia medications now tops $2,billion ...
... trouble, researchers note , THURSDAY, Oct. 4 (HealthDay ... Children,s Hospital Boston have found new information that ... a lung disease that affects premature newborns , ... or treat BPD, which can cause long-term breathing ...
... Smooth talking Mitt,Romney is heading back to the ... Bush,s veto of legislation that would provide health ... USA, September 25,2007] Despite recent polls showing that ... have provided health insurance to 10 million children,across ...
Cached Medicine News:Health News:$4 million nursing grant focuses on at-risk premature infants 2Health News:PointCross Releases Pre-Clinical Study Lifecycle and Data Management Suite (PC-LDM(TM)) For Multi-Party Environments 2Health News:Sleep Disorders: Waking Up to Reality 2Health News:Genes Give Clues to Newborn Lung Disease 2Health News:DNC: Romney an (S)CHIP Off the Bush Republican Block 2Health News:DNC: Romney an (S)CHIP Off the Bush Republican Block 3
... The STart 4 semi-automated hemostasis analyzer ... electro-mechanical clot detection (Viscosity-based Detection System). ... icteric or other optically turbid samples ... offers programmable and preprogrammed assays with ...
... The STA is a fully-automated, ... chromogenic and immunological assays in true ... method of sample management offers high ... samples without the need to interrupt ...
The CA-50 is a compact semi-automated coagulation analyzerproviding 4-parameter random access....
... The Electra 1800C is ... system that maximizes efficiency ... to the operator with ... is equipped with an ...
Medicine Products: